MedTrace Logo

Randomized Customized Adjuvant Chemotherapy (GECP-SCAT)

NCT00478699 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2024-12-12

Study results available
· View outcomes & findings →

Summary

Randomized Study of Customized Adjuvant Chemotherapy based on BRCA1 mRNA Levels in Completely Resected stages II-IIIA Non-Small-Cell Lung Cancer Patients.

Conditions

  • Non-small-cell Lung Cancer

Interventions

DRUG

Docetaxel/Cisplatin control

Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 day 1, 4 cycles

DRUG

Docetaxel

Docetaxel 75 mg/m2 day 1, 4 cycles

DRUG

Gemcitabine/Cisplatin

Gemcitabine 1250 mg/m2, day 1 and 8 and cisplatin 75 mg/m2 day 1, 4 cycles

DRUG

Docetaxel/Cisplatin

Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 day 1, 4 cycles

Sponsors & Collaborators

  • Spanish Lung Cancer Group

    lead OTHER

Principal Investigators

  • Bartomeu Massutí Sureda, MD · Hospital General Universitario de Alicante

  • Jose Miguel Sanchez Torres, MD · Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2015-06-30
Completion
2015-07-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00478699 on ClinicalTrials.gov